Sepsis has a poorer long-term survival profile than some forms of cancer, buts its clinical management is still hampered by pathology laboratory methods that rely on slow culture-based technology.
We are currently developing a suite of rapid, culture-independent methods that will accelerate recognition of sepsis, detection of the causal pathogen and determination of best antibiotic choice. Our prototype flow assisted susceptibility test method promises to set new standards for clinical laboratories.
Further, we are working with collaborating centres overseas on potential antimicrobial agent candidates for specific challenging pathogens. That gives us options for apparently untreatable infections.
Our group is often involved in developing outbreak and emerging infectious disease response capability for remote and rural communities in Australia, and work with collaborating centres in the region to improve clinical laboratory capability. This work has given us substantial experience in field investigation for emerging infections.
Researcher wins Bill & Melinda Gates Foundation Award funding
Tuesday, 31 May 2016
Medical microbiologist Professor Tim Inglis has been awarded US$100,000 (A$138,160) by the Bill & Melinda Gates Foundation to develop a screening test that will detect antibiotic resistance and ensure the right antibiotics can be prescribed.
Professor Inglis, from UWA's School of Pathology and Laboratory Medicine, said the research team's ultimate goal was to provide evidence-based support for initial antibiotic prescribing decisions.